Introduction
Globally, an estimated 2.4 million people are diagnosed with epilepsy each year. Thus, a new person is diagnosed with epilepsy every 13 s (http://www.who.int/mediacentre/factsheets/fs999/en). In 60% of those affected, epileptogenesis is initiated by structural causes such as traumatic brain injury (TBI) or stroke (Hauser et al., 1993; Scheffer et al., 2017) . Over 40 hypothesis-driven monotherapy approaches have demonstrated some disease-modifying effects in animal models of epileptogenesis (Pitkänen and Engel Jr., 2014; Pitkänen and Lukasiuk, 2011) . Currently, however, no clinical treatments are available to stop or alleviate epileptogenesis in at-risk patients or to alleviate the course of epilepsy after its diagnosis. The development of treatments to combat epileptogenesis remains a major unmet medical need and a research priority both in Europe and the USA (Baulac and Pitkänen, 2009; Kelley et al., 2009) .
One reason for the stalled progression of compounds showing proofof-concept evidence in animal models to clinical antiepileptogenesis trials is the lack of diagnostic biomarkers for epileptogenesis that could be used to stratify patient populations for antiepileptogenesis trials and reduce study costs (Engel et al., 2013) . Also, little effort has been aimed at identifying and using response biomarkers that could inform about target engagement in the early treatment development phase and provide an early go/no-go signal for further development.
Here we review the current status of biomarker discovery in epilepsy, using the BEST (Biomarkers, EndpointS, and other Tools) recommendations for categorizing the different types of epilepsy biomarkers (https://www.ncbi.nlm.nih.gov/books/NBK326791/). In addition, we outline the epilepsy-related challenges that need to be discussed and solved to further the progress in biomarker discovery for different epilepsy indications (Table 1) .
